Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

doi:10.1093/infdis/jiv363

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

The Journal of infectious diseases - 1 Jan 2016

Hermans Lucas Etienne, Svicher Valentina, Pas Suzan Diepstraten, Salpini Romina, Alvarez Marta, Ben Ari Ziv, Boland Greet, Bruzzone Bianca, Coppola Nicola, Seguin-Devaux Carole, Dyda Tomasz, Garcia Federico, Kaiser Rolf, Köse Sukran, Krarup Henrik, Lazarevic Ivana, Lunar Maja M, Maylin Sarah, Micheli Valeria, Mor Orna, Paraschiv Simona, Paraskevis Dimitrios, Poljak Mario, Puchhammer-Stöckl Elisabeth, Simon François, Stanojevic Maja, Stene-Johansen Kathrine, Tihic Nijaz, Trimoulet Pascale, Verheyen Jens, Vince Adriana, Weis Nina, Yalcinkaya Tülay, Lepej Snjezana Zidovec, Perno Carlo, Boucher Charles A B, Wensing Annemarie M J

Abstract excerpt

BACKGROUND: European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. METHODS: A survey was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Cross-Sectional Studies

Share to Drug Resistance, Viral

Share to Genotype

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Prevalence

Source

Open in PubMed

Identifiers

PMID: 26136470
DOI: 10.1093/infdis/jiv363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).PMID 26136470Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

Treatment for hepatitis B in patients with drug resistanceSemantic proximity Read ↗

Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).Semantic proximity Read ↗

Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Semantic proximity Read ↗

Viral resistance in hepatitis B: prevalence and management.Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.